Melanoma cell adhesion molecule as an emerging biomarker with prognostic significance in systolic heart failure

Biomark Med. 2016 Jul;10(7):733-42. doi: 10.2217/bmm-2016-0053. Epub 2016 Jun 29.

Abstract

Background: Melanoma cell adhesion molecule (MCAM) is a marker of endothelial damage. MCAM diagnostic and prognostic value was assessed in chronic heart failure (CHF).

Materials & methods: 130 CHF patients and 32 controls were included in the study. Telephone follow-up lasted one year. End points were: death from all causes, and hospitalization with CHF exacerbation.

Results: MCAM was higher in patients than in controls (p = 0.01). Receiver operator curve analysis revealed that MCAM may serve as a predictor of death (area under the curve: 0.8404; p < 0.002). Patients with MCAM above 500 ng/ml had worse prognosis (p = 0.03). NT-proBNP and age were independent predictors of death in multivariate analysis.

Conclusion: The increased MCAM indicates endothelial damage in CHF and may serve as a marker of worse prognosis in these patients.

Keywords: chronic heart failure; melanoma cell adhesion molecule; prognosis.

MeSH terms

  • Aged
  • Area Under Curve
  • Biomarkers / blood*
  • C-Reactive Protein / analysis
  • CD146 Antigen / blood
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Heart Failure, Systolic / diagnosis*
  • Heart Failure, Systolic / mortality
  • Heart Failure, Systolic / pathology
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Natriuretic Peptide, Brain / blood
  • Peptide Fragments / blood
  • Prognosis
  • Proportional Hazards Models
  • ROC Curve
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • CD146 Antigen
  • MCAM protein, human
  • Peptide Fragments
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • C-Reactive Protein